Companies

Astria Therapeutics Inc

NASDAQ: ATXS
$12.58
▲ $0.00 (+0.00%) today
Markets closed · 5:27am ET
Today · % change

About Astria Therapeutics

Astria Therapeutics, Inc. is a Boston-based biopharmaceutical firm dedicated to developing treatments for rare and specialized allergic and immunological diseases. Its flagship project, STAR-0215, is a pioneering monoclonal antibody aimed at treating hereditary angioedema, currently in the clinical trial phase. Originally known as Catabasis Pharmaceuticals, Astria rebranded in 2021, continuing its mission since its inception in 2008 to address unmet medical needs in niche disease areas.

ATXS Coverage